Erectile Dysfunction

Hesselberg worked for Immunex Corporation and the Puget Sound Blood Center.

Mr.

Hesselberg holds a B.S.

in Molecular Biology from the University of Wisconsin-Madison and a MBA from the University of Washington.

About GTx GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions.

GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN.

GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®.

GTx also is developing Ostarine™, a first-in-class selective androgen receptor modulator, or SARM.

GTx plans to initiate a Phase IIb Ostarine™ clinical trial for cancer cachexia by the summer of 2007.

GTx plans to initiate a Phase IIb Ostarine™ clinical trial for the treatment of chronic kidney disease and end stage renal disease muscle wasting by ...

The drug enhanced engorgement of vaginal tissue, just as it had of the penis, but that extra bit of pelvic swelling did nothing to amplify women's desire for or enjoyment of sex.

What is needed for the treatment of so-called female hypoactive sexual desire disorder, researchers decided, is a reasonably safe and effective drug that acts on the central nervous system, on the pleasure centers of the brain.

For a while, many sex therapists and doctors were optimistic about Procter & Gamble's Intrinsa, a testosterone patch that delivers small transdermal pulses of the sex hormone thought to play a crucial if poorly understood role in male and female libido alike.

But in 2005, the Food and Drug Administration refused to approve Intrinsa, declaring that its medical risks outweighed whatever benefits it might offer.

More recently, another potentially promising treatment for hypoactive desire has been making its way through clinical trials.

The compound, called bremelanotide, is a synthetic version of a hormone involved in skin pigmentation, and it was initially developed by Palatin Technologies of New Jersey as a potential tanning agent to help prevent skin cancer.

But when male college students participating in early tests began reporting that the drug sometimes gave them erections, the company began exploring bremelanotide's utility as a treatment for sexual disorders.

Studies...